Last checked at 
(For more market insights, including options activity, click on ; for the Day Ahead newsletter http://link.reuters.com/mex49s; for the Morning News Call newsletter, http://link.reuters.com/nex49s)Wall Street rebounded modestly on Monday after its worst weeksince June 2012, with investors focused on corporate earningsfrom big names like Caterpillar and Apple. The Dow Jonesindustrial average was up 0.19 percent at 15,909.01, theS&P 500 was up 0.12 percent at 1,792.35 and the NasdaqComposite was down 0.14 percent at 4,122.271.
** APPLE INC, $551.9, +1.07 pct
The iPhone maker may notch its most successful holidayshopping season yet when it reports quarterly results aftermarkets close, setting records for sales of its gift-friendlyiPhones and iPads.
** CATERPILLAR INC, $91.33, +5.99 pct
Caterpillar posted a stronger-than-expected quarterly profiton Monday as the world's largest mining and constructionequipment aggressively cut costs to offset continued sluggishsales of its earth-moving equipment.
** AT&T, $33.46, +0.12 pct
** VODAFONE GROUP PLC, $37.18, -2.26 pct
** VERIZON COMMUNICATIONS INC, $48.02, +0.82 pct
** SPRINT CORP, $8.88, +5.71 pct
U.S. mobile group AT&T has ruled out a bid for Britain'sVodafone for now, with banking sources saying a U.S. spyingscandal and a surge in European telecom shares may havedisrupted a deal that many think could stillhappen.
** ROYAL CARIBBEAN, $48.74, +3.42 pct
** CARNIVAL CORP, $39.88, +1.86 pct
The world's second-largest cruise operator reported afourth-quarter profit, compared to a year-earlier loss, buoyedby increased bookings in most markets.
Carnival Corp shares were also up on the news.
** GERON CORP, $4.7304, -15.83 pct
The company said about 20 patients enrolled in a trialtesting its cancer drug, imetelstat, dropped out of the study.The company said the investigator-sponsored trial had enrolled79 patients since it started. The study was testing imetelstatin patients with myelofibrosis and other myeloid malignancies, agroup of blood cancers.
** YINGLI GREEN ENERGY HOLDING COMPANY LTD, $6.12,+4.44 pct
** CANADIAN SOLAR INC, $38.54, +3.46 pct
** TRINA SOLAR LTD, $14.29, +4.92 pct
** JINKOSOLAR HOLDING CO LTD, $30.25, +1.85 pct
** JA SOLAR HOLDINGS CO LTD, $8.99, +2.28 pct
** RENESOLA LTD, $3.47, +2.36 pct
** FIRST SOLAR INC, $49.82, +2.36 pct
** SOLARCITY CORP, $71.2101, +1.04 pct
** SUNPOWER CORP, $31.6838, +1.75 pct
Analysts at Roth Capital said confusion regarding China'stargeted demand for solar consumption in 2014, along with theongoing U.S.-China trade war and U.S. suspension of Chineseunits of four accounting firms weighed on the solar companies'stocks. Analysts said the U.S. trade officials' investigationinto imports of certain solar products from China and Taiwan,and the SEC suspension of accounting firms represent potentialnear-term industry headwinds.
The investigation could bar import of modules assembled inChina into the U.S. market, resulting in higher prices and lowerdemand. "Not only could this adversely impact Chinese modulemanufacturers and Taiwanese cell manufacturers, but it couldalso negatively impact downstream companies in the US and the USmarket overall," analysts said in a note.
** SHANDA GAMES LTD, $6.25, +10.62 pct
The Chinese online game developer said it received a $1.9billion buyout offer from a consortium led by its controllingshareholder.
** INTEGRATED DEVICE TECHNOLOGY INC, $10.025, -4.25pct
Barclays Capital cut its rating on the chip-componentmaker's stock to "underweight" from "equal weight," saying thestock was reflecting insufficient concern for revenue headwindsafter its cost-cutting efforts.
** BIOCRYST PHARMACEUTICALS INC, $10.9, -6.03 pct
Wells Fargo analyst Brian Abrahams cut his rating on thestock to "market perform" from "outperform," saying thecompany's current valuation reflected potential revenue from itsinfluenza injection and the promise of its experimental drug totreat hereditary angioedema, a rare disease characterized byswelling of the body.
** YRC WORLDWIDE INC, $19.88, +5.80 pct
Teamsters union members have approved YRC Worldwide'srevised labor contract, clearing the way for the strugglingtrucking company to proceed with its refinancing plans.
** PEABODY ENERGY CORP, $17.1, +1.36 pct
Analysts at BofA Merrill Lynch raised their rating on theU.S. coal miner to "neutral" from "underperform", according toTheflyonthewall.com
** FACEBOOK INC, $53.92, -0.97 pct
Brokerage Cantor Fitzgerald raised its price target on thesocial network's stock to $65 from $63 and said it expectsFacebook to report solid fourth-quarter results on Wednesday,driven mainly by higher mobile ad revenue.
** BOEING CO, $137.921, +0.93 pct
The airplane maker said on Friday it is producing its 787Dreamliner at the highest ever rate of 10 per month, a milestonethe company had hoped to achieve by the end of 2013.
** CISCO SYSTEMS INC, $22.0003, -0.90 pct
JPMorgan cut its rating on Cisco's stock to "underweight"from "neutral," citing weakness in emerging markets serviceproviders and delayed spending in the switching market driven bysoftware-defined networking. The brokerage cut its price targeton the stock to $17 from $21.
** PROCTER & GAMBLE CO, $78.76, -0.53 pct
** KIMBERLY-CLARK CORP, $107.44, +0.04 pct
The companies, two of the world's biggest household productsmakers, forecast strong sales gains in emerging markets onFriday, quelling investor fears that slowing growth in somecountries would hurt their prospects. P&G, the maker of Pampersdiapers and Tide detergent, said revenue rose 8 percent indeveloping countries in its fiscal second quarter, but barelyedged up in mature markets like the United States and Europe. Itstuck to its 2014 sales and profit forecasts. Kimberly-Clarkreported similar gains in emerging markets, helped by stronggrowth in China, and gave an upbeat 2014 forecast.
** LIBERTY GLOBAL, $81.63, -1.97 pct
The U.S. cable group has agreed to buy Ziggo in acash-and-share deal valuing the Dutch operator at 10 billioneuros ($13.7 billion) to expand its reach across Europe.
** GOOGLE INC, $1,111, -1.14 pct
Google and Samsung Electronics Co Ltd, which arefrequently involved in patent infringement lawsuits but notagainst each other, announced on Sunday that they have reached aglobal patent cross-licensing agreement.
** TEVA PHARMACEUTICAL INDUSTRIES, $43.39, +1.07pct
An EMA committee on Friday said it had concerns about animalstudies showing a higher occurrence of cancers after long-termexposure to Teva's multiple sclerosis (MS) drug laquinimod. (Compiled by Sruthi Ramakrishnan in Bangalore; Editing byJoyjeet Das)
